Mildred Mandisa Mdingi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mildred Mandisa Mdingi has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Remco Petrus Peters
Department of Medical Microbiology, University of Pretoria, Pretoria, South Africa
13 shared publications - Hyunsul Jung
Department of Medical Microbiology, University of Pretoria, Pretoria, South Africa
8 shared publications Jeffrey D Klausner
Department of Population and Public Health Sciences, Keck School of Medicine of University of Southern California , Los Angeles, California
7 shared publications- Ranjana Ms Gigi
Research Unit, Foundation for Professional Development , East London
7 shared publications - Chibuzor M. Babalola
Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California
6 shared publications - Christina A. Muzny
Division of Infectious Diseases, University of Alabama at Birmingham , Birmingham, Alabama
6 shared publications
Latest Publications
- Open Access
Molecular typing and characterisation of antimicrobial resistance determinants of Neisseria gonorrhoeae among symptomatic individuals in the Eastern Cape, South Africa
Background: Antimicrobial resistance in Neisseria gonorrhoeae threatens gonorrhoea treatment, while surveillance is constrained by limited culture capacity. We evaluated multi-antigen sequence typing (NG-MAST) and targeted real-time PCR for molecular epidemiology and detection of antimicrobial resistance-associated determinants directly from clinical specimens. Methods: We analysed 235 N. gonorrhoeae -positive stored DNA extracts from symptomatic individuals in South Africa. NG-MAST sequence types were obtained directly or from whole-genome sequences (WGS) of paired cultured isolates. Real-time PCR targeted fluoroquinolone resistance-associated mutations (RAMs) in parC and gyrA and macrolide RAMs in the 23S rRNA gene. Results were compared with WGS and with phenotypic susceptibility results from paired isolates. Results: NG-MAST sequence types were obtained for 200/235 (85.1%) specimens and were diverse, with ST21253 predominating (n=26). At least one gyrA or parC mutation was detected by real-time PCR in 110/193 (57.0%) specimens. Compared with WGS, positive agreement was 81.2% for parC and 97.0% for gyrA , and negative agreement 100% and 95.8%, respectively. Among 65 ciprofloxacin-resistant isolates, RAMs were detected in 60 (92.3%) by real-time PCR and 61 (93.8%) by WGS; four had no RAM detected by either method. The 23S rRNA C2611T mutation was detected by both methods in one isolate (azithromycin MIC, 8 mg/L); no A2059G mutations were detected. Conclusions: Gonococcal sequence types were diverse, fluoroquinolone RAMs were common, and the assessed macrolide RAMs were rare. Real-time PCR applied directly to specimen DNA agreed well with WGS, but the targeted markers did not fully predict ciprofloxacin susceptibility, supporting complementary molecular and phenotypic approaches.
Open AccessMolecular typing and characterisation of antimicrobial resistance determinants of Neisseria gonorrhoeae among symptomatic individuals in the Eastern Cape, South Africa
Background: Antimicrobial resistance in Neisseria gonorrhoeae threatens gonorrhoea treatment, while surveillance is constrained by limited culture capacity. We evaluated multi-antigen sequence typing (NG-MAST) and targeted real-time PCR for molecular epidemiology and detection of antimicrobial resistance-associated determinants directly from clinical specimens. Methods: We analysed 235 N. gonorrhoeae -positive stored DNA extracts from symptomatic individuals in South Africa. NG-MAST sequence types were obtained directly or from whole-genome sequences (WGS) of paired cultured isolates. Real-time PCR targeted fluoroquinolone resistance-associated mutations (RAMs) in parC and gyrA and macrolide RAMs in the 23S rRNA gene. Results were compared with WGS and with phenotypic susceptibility results from paired isolates. Results: NG-MAST sequence types were obtained for 200/235 (85.1%) specimens and were diverse, with ST21253 predominating (n=26). At least one gyrA or parC mutation was detected by real-time PCR in 110/193 (57.0%) specimens. Compared with WGS, positive agreement was 81.2% for parC and 97.0% for gyrA , and negative agreement 100% and 95.8%, respectively. Among 65 ciprofloxacin-resistant isolates, RAMs were detected in 60 (92.3%) by real-time PCR and 61 (93.8%) by WGS; four had no RAM detected by either method. The 23S rRNA C2611T mutation was detected by both methods in one isolate (azithromycin MIC, 8 mg/L); no A2059G mutations were detected. Conclusions: Gonococcal sequence types were diverse, fluoroquinolone RAMs were common, and the assessed macrolide RAMs were rare. Real-time PCR applied directly to specimen DNA agreed well with WGS, but the targeted markers did not fully predict ciprofloxacin susceptibility, supporting complementary molecular and phenotypic approaches.
- Open Access
- 27 October 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Antenatal Screening for Sexually Transmitted Infections to Reduce Preterm Birth or Low Birthweight (Philani Ndiphile Study): A Randomized 3-Group Trial
Background: Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis are predominantly asymptomatic curable sexually transmitted infections (STIs) associated with adverse birth outcomes. Whether antenatal STI screening improves birth outcomes remains uncertain. Methods: In this randomized trial (NCT04446611), pregnant women ≥18 years were assigned before 27 weeks' gestation to (1) screening and treatment for C. trachomatis, N. gonorrhoeae, and T. vaginalis at enrollment, with tests-of-cure (1-Time Screening); (2) screening and treatment at enrollment, repeated at 30–34 weeks (2-Time Screening); or (3) Standard-of-Care (syndromic management). The primary outcome was a composite of preterm birth (<37 weeks' gestation) or low birthweight (<2500 g); each component was evaluated individually as a secondary outcome. Results: Of 2247 enrolled, 1910 had live births. The composite outcome occurred in 22.9% of the 1-Time Screening (RR 0.99; 95% CI .81–1.21) and 20.6% of the 2-Time Screening groups (RR 0.89; 95% CI .72–1.09), compared with 23.2% of the Standard-of-Care group. Preterm birth occurred in 18.9% of the 1-Time Screening group (RR 1.00; 95% CI .80–1.26), 14.5% of the 2-Time Screening group (RR 0.77; 95% CI .60–0.99), and 18.8% of the Standard-of-Care group. Low birthweight occurred in 14.1% of the 1-Time Screening group (RR 1.10; 95% CI .83–1.46), 12.9% of the 2-Time Screening group (RR 1.01; 95% CI .76–1.35), and 12.8% of the Standard-of-Care group. Conclusions: Neither STI screening strategy reduced the primary composite outcome or low birthweight alone. The 2-Time Screening strategy reduced preterm birth by 23%.
- 27 October 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Open AccessAntenatal Screening for Sexually Transmitted Infections to Reduce Preterm Birth or Low Birthweight (Philani Ndiphile Study): A Randomized 3-Group Trial
Background: Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis are predominantly asymptomatic curable sexually transmitted infections (STIs) associated with adverse birth outcomes. Whether antenatal STI screening improves birth outcomes remains uncertain. Methods: In this randomized trial (NCT04446611), pregnant women ≥18 years were assigned before 27 weeks' gestation to (1) screening and treatment for C. trachomatis, N. gonorrhoeae, and T. vaginalis at enrollment, with tests-of-cure (1-Time Screening); (2) screening and treatment at enrollment, repeated at 30–34 weeks (2-Time Screening); or (3) Standard-of-Care (syndromic management). The primary outcome was a composite of preterm birth (<37 weeks' gestation) or low birthweight (<2500 g); each component was evaluated individually as a secondary outcome. Results: Of 2247 enrolled, 1910 had live births. The composite outcome occurred in 22.9% of the 1-Time Screening (RR 0.99; 95% CI .81–1.21) and 20.6% of the 2-Time Screening groups (RR 0.89; 95% CI .72–1.09), compared with 23.2% of the Standard-of-Care group. Preterm birth occurred in 18.9% of the 1-Time Screening group (RR 1.00; 95% CI .80–1.26), 14.5% of the 2-Time Screening group (RR 0.77; 95% CI .60–0.99), and 18.8% of the Standard-of-Care group. Low birthweight occurred in 14.1% of the 1-Time Screening group (RR 1.10; 95% CI .83–1.46), 12.9% of the 2-Time Screening group (RR 1.01; 95% CI .76–1.35), and 12.8% of the Standard-of-Care group. Conclusions: Neither STI screening strategy reduced the primary composite outcome or low birthweight alone. The 2-Time Screening strategy reduced preterm birth by 23%.
- Open Access
Mycoplasma genitalium infection and adverse pregnancy outcomes among pregnant women in South Africa: prospective cohort study
Background: Sexually transmitted infections (STIs) and vaginal dysbiosis during pregnancy are associated with adverse pregnancy outcomes. Mycoplasma genitalium is the most recent STI implicated but evidence remains limited. The objectives of this study were to investigate 1) the association between M. genitalium infection during pregnancy and gestational age at delivery, preterm birth, miscarriage or stillbirth, and low birth weight and 2) the interaction with vaginal dysbiosis. Methods: We conducted a prospective cohort study in East London, South Africa. We enrolled pregnant women at gestational age M. genitalium , Chlamydia trachomatis , Neisseria gonorrhoeae , Trichomonas vaginalis , other genital mycoplasmas and Candida spp. We defined vaginal dysbiosis using Gram-stain criteria as a Nugent score 4-10. We used quantile regression to compare the outcome in women with and without M. genitalium across the gestational age distribution, adjusting for prespecified sociodemographic and clinical characteristics and co-occurring organisms. Results: From April 1, 2021 to August 29, 2023, we enrolled 603 women, followed up 584 and obtained pregnancy outcomes for 560 (93%). Median age was 28 years (interquartile range, IQR 24, 33) and 27% of women were living with HIV. M. genitalium was detected in 44/584 (8%, 95% CI 6, 10%) and vaginal dysbiosis in 375/584 (64%) of women. Median gestational age at delivery was 39 weeks +0 days (IQR 37+4, 40+1) in women with and 39 weeks +0 days (37+4, 40+0) in those without M. genitalium . In multivariable models, associations were not observed for any adverse birth outcomes. There was no interaction between M. genitalium and vaginal dysbiosis. Discussion: M. genitalium in pregnancy was not associated with earlier gestational age at delivery or with other adverse birth outcomes. These findings do not support routine testing and treatment for M. genitalium in pregnancy.
Open AccessMycoplasma genitalium infection and adverse pregnancy outcomes among pregnant women in South Africa: prospective cohort study
Background: Sexually transmitted infections (STIs) and vaginal dysbiosis during pregnancy are associated with adverse pregnancy outcomes. Mycoplasma genitalium is the most recent STI implicated but evidence remains limited. The objectives of this study were to investigate 1) the association between M. genitalium infection during pregnancy and gestational age at delivery, preterm birth, miscarriage or stillbirth, and low birth weight and 2) the interaction with vaginal dysbiosis. Methods: We conducted a prospective cohort study in East London, South Africa. We enrolled pregnant women at gestational age M. genitalium , Chlamydia trachomatis , Neisseria gonorrhoeae , Trichomonas vaginalis , other genital mycoplasmas and Candida spp. We defined vaginal dysbiosis using Gram-stain criteria as a Nugent score 4-10. We used quantile regression to compare the outcome in women with and without M. genitalium across the gestational age distribution, adjusting for prespecified sociodemographic and clinical characteristics and co-occurring organisms. Results: From April 1, 2021 to August 29, 2023, we enrolled 603 women, followed up 584 and obtained pregnancy outcomes for 560 (93%). Median age was 28 years (interquartile range, IQR 24, 33) and 27% of women were living with HIV. M. genitalium was detected in 44/584 (8%, 95% CI 6, 10%) and vaginal dysbiosis in 375/584 (64%) of women. Median gestational age at delivery was 39 weeks +0 days (IQR 37+4, 40+1) in women with and 39 weeks +0 days (37+4, 40+0) in those without M. genitalium . In multivariable models, associations were not observed for any adverse birth outcomes. There was no interaction between M. genitalium and vaginal dysbiosis. Discussion: M. genitalium in pregnancy was not associated with earlier gestational age at delivery or with other adverse birth outcomes. These findings do not support routine testing and treatment for M. genitalium in pregnancy.
- Open Access
Cost-effectiveness and cost-utility of antenatal sexually transmitted infection screening to reduce preterm birth and low birthweight in South Africa
Background: Curable sexually transmitted infections (STIs) are associated with adverse birth outcomes, yet little cost-effectiveness evidence guides antenatal STI screening policy in high-burden settings. We conducted a cost-effectiveness and cost-utility analysis of the Philani Ndiphile trial in South Africa, comparing One-Time and Two-Time antenatal screening for C. trachomatis, N. gonorrhoeae, and T. vaginalis with standard syndromic management. Methods: A decision-analytic model from the provider perspective simulated costs and outcomes for pregnant women and infants. Costs included diagnostics, treatment, and neonatal hospitalisation for a primary composite outcome of preterm birth and/or low birthweight and its components (secondary trial outcomes). Modelled outcomes included incremental cost (US$) per composite (preterm birth and/or low birthweight) case, per component case and per disability-adjusted life year (DALY) averted. The analysis captured infant outcomes in the first year. Univariate and probabilistic sensitivity analyses were conducted to assess parameter uncertainty and robustness of results. Results: Screening for C. trachomatis, N. gonorrhoeae, and T. vaginalis twice during pregnancy was not cost-effective for preventing the primary composite outcome, nor for preventing low birthweight alone. However, two-time screening was cost-saving for preventing preterm birth alone, averting more DALYs and thereby yielding better health outcomes while reducing healthcare costs compared with syndromic management. One-time screening was not cost-effective for preventing any outcome. Conclusions: Repeat antenatal screening for C. trachomatis, N. gonorrhoeae , and T. vaginalis has the potential to prevent preterm births while reducing healthcare costs in high-burden settings. These findings support further research to confirm the clinical effectiveness of repeat screening and to evaluate longer-term health and economic impacts.
Open AccessCost-effectiveness and cost-utility of antenatal sexually transmitted infection screening to reduce preterm birth and low birthweight in South Africa
Background: Curable sexually transmitted infections (STIs) are associated with adverse birth outcomes, yet little cost-effectiveness evidence guides antenatal STI screening policy in high-burden settings. We conducted a cost-effectiveness and cost-utility analysis of the Philani Ndiphile trial in South Africa, comparing One-Time and Two-Time antenatal screening for C. trachomatis, N. gonorrhoeae, and T. vaginalis with standard syndromic management. Methods: A decision-analytic model from the provider perspective simulated costs and outcomes for pregnant women and infants. Costs included diagnostics, treatment, and neonatal hospitalisation for a primary composite outcome of preterm birth and/or low birthweight and its components (secondary trial outcomes). Modelled outcomes included incremental cost (US$) per composite (preterm birth and/or low birthweight) case, per component case and per disability-adjusted life year (DALY) averted. The analysis captured infant outcomes in the first year. Univariate and probabilistic sensitivity analyses were conducted to assess parameter uncertainty and robustness of results. Results: Screening for C. trachomatis, N. gonorrhoeae, and T. vaginalis twice during pregnancy was not cost-effective for preventing the primary composite outcome, nor for preventing low birthweight alone. However, two-time screening was cost-saving for preventing preterm birth alone, averting more DALYs and thereby yielding better health outcomes while reducing healthcare costs compared with syndromic management. One-time screening was not cost-effective for preventing any outcome. Conclusions: Repeat antenatal screening for C. trachomatis, N. gonorrhoeae , and T. vaginalis has the potential to prevent preterm births while reducing healthcare costs in high-burden settings. These findings support further research to confirm the clinical effectiveness of repeat screening and to evaluate longer-term health and economic impacts.
- Open Access
- 22 April 2026
- Published by BMJ in Sexually Transmitted Infections
- Vol. 102 (Suppl 2) , s126-s127
SpiroTact and VIPER technology: a promising rapid point-of-care test for active syphilis
- 22 April 2026
- Published by BMJ in Sexually Transmitted Infections
- Vol. 102 (Suppl 2) , s126-s127
Open AccessSpiroTact and VIPER technology: a promising rapid point-of-care test for active syphilis
- Open Access
Antenatal Screening for Sexually Transmitted Infections to Reduce Preterm Birth or Low Birthweight (Philani Ndiphile Study): A Randomized Three-Group Trial
SUMMARY: Background: Chlamydia trachomatis , Neisseria gonorrhoeae , and Trichomonas vaginalis are curable sexually transmitted infections (STIs) associated with adverse birth outcomes. Most infections are asymptomatic. Whether antenatal STI screening improves birth outcomes remains uncertain. Methods: In a randomized three-group trial in South Africa, pregnant women aged 18 years or older were assigned before 27 weeks’ gestation to: (1) screening and treatment for Chlamydia trachomatis, Neisseria gonorrhoeae , and Trichomonas vaginalis at enrollment, with tests-of-cure (One-Time Screening); (2) screening and treatment at enrollment, repeated at 30 to 34 weeks (Two-Time Screening); or (3) Standard-of-Care (Syndromic management). The primary outcome was a composite of preterm birth (Chlamydia trachomatis , Neisseria gonorrhoeae , and Trichomonas vaginalis reduced the primary composite outcome of preterm birth or low birthweight, or low birthweight alone. The Two-Time antenatal STI screening strategy, however, reduced preterm birth by 23%.
Open AccessAntenatal Screening for Sexually Transmitted Infections to Reduce Preterm Birth or Low Birthweight (Philani Ndiphile Study): A Randomized Three-Group Trial
SUMMARY: Background: Chlamydia trachomatis , Neisseria gonorrhoeae , and Trichomonas vaginalis are curable sexually transmitted infections (STIs) associated with adverse birth outcomes. Most infections are asymptomatic. Whether antenatal STI screening improves birth outcomes remains uncertain. Methods: In a randomized three-group trial in South Africa, pregnant women aged 18 years or older were assigned before 27 weeks’ gestation to: (1) screening and treatment for Chlamydia trachomatis, Neisseria gonorrhoeae , and Trichomonas vaginalis at enrollment, with tests-of-cure (One-Time Screening); (2) screening and treatment at enrollment, repeated at 30 to 34 weeks (Two-Time Screening); or (3) Standard-of-Care (Syndromic management). The primary outcome was a composite of preterm birth (Chlamydia trachomatis , Neisseria gonorrhoeae , and Trichomonas vaginalis reduced the primary composite outcome of preterm birth or low birthweight, or low birthweight alone. The Two-Time antenatal STI screening strategy, however, reduced preterm birth by 23%.
- Open Access
Implementation of point-of-care screening for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis among pregnant women in South Africa: a mixed-methods process evaluation of the Philani Ndiphile trial
Background: Curable sexually transmitted infections (STIs), including Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis, remain highly prevalent among pregnant women in South Africa. Despite poor diagnostic performance in pregnancy, syndromic management remains standard care. Point-of-care (POC) screening enables aetiological diagnosis and same-visit treatment but is not yet included in national guidelines. We conducted a mixed-methods process evaluation to examine determinants of antenatal POC STI screening implementation in public facilities. Methods: This evaluation was embedded within the three-arm Philani Ndiphile randomized trial (March 2021-February 2025) across four public clinics in the Eastern Cape. Screening used a near-POC, electricity-dependent nucleic acid amplification test with a 90-minute turnaround time. Reach, Adoption, Implementation, and Maintenance were assessed using the RE-AIM framework. Quantitative indicators included uptake of screening, treatment, and follow-up attendance. Qualitative data included in-depth interviews with 20 pregnant women and five focus group discussions with 21 research staff and government healthcare workers. The Consolidated Framework for Implementation Research guided qualitative analysis. Findings were integrated using narrative weaving. Results: Screening uptake was high (99.0%), with treatment coverage of 95.2% at baseline and 93.5% at repeat screening. Same-day treatment was lower (50.7% and 69.8%) and varied substantially by facility, reflecting operational constraints including turnaround time, patient volume, infrastructure, and electricity. Attendance was higher when screening was integrated into routine ANC. Women valued screening for infant health, while providers recognised advantages over syndromic management but highlighted workforce, resource, and maintenance constraints. Socioeconomic factors, including transport costs, hunger, and work commitments, influenced retention and waiting. Conclusions: Antenatal POC STI screening was acceptable and achieved high treatment coverage in a research setting. However, same-day treatment was constrained by operational requirements of the testing platform. Scale-up will require workflow integration, strengthened health system capacity, and faster diagnostics suited to routine antenatal care.
Open AccessImplementation of point-of-care screening for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis among pregnant women in South Africa: a mixed-methods process evaluation of the Philani Ndiphile trial
Background: Curable sexually transmitted infections (STIs), including Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis, remain highly prevalent among pregnant women in South Africa. Despite poor diagnostic performance in pregnancy, syndromic management remains standard care. Point-of-care (POC) screening enables aetiological diagnosis and same-visit treatment but is not yet included in national guidelines. We conducted a mixed-methods process evaluation to examine determinants of antenatal POC STI screening implementation in public facilities. Methods: This evaluation was embedded within the three-arm Philani Ndiphile randomized trial (March 2021-February 2025) across four public clinics in the Eastern Cape. Screening used a near-POC, electricity-dependent nucleic acid amplification test with a 90-minute turnaround time. Reach, Adoption, Implementation, and Maintenance were assessed using the RE-AIM framework. Quantitative indicators included uptake of screening, treatment, and follow-up attendance. Qualitative data included in-depth interviews with 20 pregnant women and five focus group discussions with 21 research staff and government healthcare workers. The Consolidated Framework for Implementation Research guided qualitative analysis. Findings were integrated using narrative weaving. Results: Screening uptake was high (99.0%), with treatment coverage of 95.2% at baseline and 93.5% at repeat screening. Same-day treatment was lower (50.7% and 69.8%) and varied substantially by facility, reflecting operational constraints including turnaround time, patient volume, infrastructure, and electricity. Attendance was higher when screening was integrated into routine ANC. Women valued screening for infant health, while providers recognised advantages over syndromic management but highlighted workforce, resource, and maintenance constraints. Socioeconomic factors, including transport costs, hunger, and work commitments, influenced retention and waiting. Conclusions: Antenatal POC STI screening was acceptable and achieved high treatment coverage in a research setting. However, same-day treatment was constrained by operational requirements of the testing platform. Scale-up will require workflow integration, strengthened health system capacity, and faster diagnostics suited to routine antenatal care.
- Open Access
- 9 February 2026
- Published by F1000 Research Ltd in VeriXiv
SpiroTact® and VIPER technology: a promising rapid point-of-care test for active syphilis
- 9 February 2026
- Published by F1000 Research Ltd in VeriXiv
Open AccessSpiroTact® and VIPER technology: a promising rapid point-of-care test for active syphilis
- 9 February 2026
- Published by BMJ in Sexually Transmitted Infections
- Vol. 102 (Suppl 2) , s52-s55
Cross-sectional evaluation of a lateral flow assay for point-of-care detection of Neisseria gonorrhoeae in asymptomatic individuals at primary healthcare facilities in South Africa
Objectives: Neisseria gonorrhoeae infection is a global health concern. An affordable and rapid point-of-care test is essential to optimise clinical care and could be used to detect and treat asymptomatic infection. Previously, a novel lateral flow assay for N. gonorrhoeae infection (NG LFA) met WHO test performance requirements in a symptomatic population. This study aimed to determine the performance of the NG LFA for detection of N. gonorrhoeae in people without symptoms. Methods: In this cross-sectional study, we evaluated a novel N. gonorrhoeae lateral flow assay in urine from 500 asymptomatic men and vaginal swabs from 400 asymptomatic women in South Africa. Individuals visiting four primary healthcare facilities in the Buffalo City district, South Africa were enrolled if they were adults (18–49 years) and did not report any genitourinary symptoms, regardless of the reason for visiting the facility. First-void urine specimens and nurse-collected vaginal swabs were tested onsite with the NG-LFA and compared with the Xpert CT/NG assay. Discordant specimens were further investigated. Results: Between March and July 2023, we enrolled 500 male and 400 female participants. The median age of male participants was 21 years (range: 18–49 years), and female participants, 32 years (range: 18–49 years). In urine specimens, NG-LFA sensitivity was 80.6% (Wilson 95% CI 63.7 to 90.8) and 81.8% in vaginal swab specimens (65·6–91.4). The specificity was 94.2% in urine specimens (91.8 to 96.0) and 98.1% in vaginal specimens (96.1 to 99.1). All NG-LFA positive/Xpert negative cases were negative for N. gonorrhoeae or other Neisseria species in additional molecular testing. Conclusions: The NG LFA in vaginal swab specimens met WHO criteria for a screening test in low-resource settings. The NG LFA in male urine specimens met sensitivity criteria but did not meet the criteria for specificity.
- 9 February 2026
- Published by BMJ in Sexually Transmitted Infections
- Vol. 102 (Suppl 2) , s52-s55
Cross-sectional evaluation of a lateral flow assay for point-of-care detection of Neisseria gonorrhoeae in asymptomatic individuals at primary healthcare facilities in South Africa
Objectives: Neisseria gonorrhoeae infection is a global health concern. An affordable and rapid point-of-care test is essential to optimise clinical care and could be used to detect and treat asymptomatic infection. Previously, a novel lateral flow assay for N. gonorrhoeae infection (NG LFA) met WHO test performance requirements in a symptomatic population. This study aimed to determine the performance of the NG LFA for detection of N. gonorrhoeae in people without symptoms. Methods: In this cross-sectional study, we evaluated a novel N. gonorrhoeae lateral flow assay in urine from 500 asymptomatic men and vaginal swabs from 400 asymptomatic women in South Africa. Individuals visiting four primary healthcare facilities in the Buffalo City district, South Africa were enrolled if they were adults (18–49 years) and did not report any genitourinary symptoms, regardless of the reason for visiting the facility. First-void urine specimens and nurse-collected vaginal swabs were tested onsite with the NG-LFA and compared with the Xpert CT/NG assay. Discordant specimens were further investigated. Results: Between March and July 2023, we enrolled 500 male and 400 female participants. The median age of male participants was 21 years (range: 18–49 years), and female participants, 32 years (range: 18–49 years). In urine specimens, NG-LFA sensitivity was 80.6% (Wilson 95% CI 63.7 to 90.8) and 81.8% in vaginal swab specimens (65·6–91.4). The specificity was 94.2% in urine specimens (91.8 to 96.0) and 98.1% in vaginal specimens (96.1 to 99.1). All NG-LFA positive/Xpert negative cases were negative for N. gonorrhoeae or other Neisseria species in additional molecular testing. Conclusions: The NG LFA in vaginal swab specimens met WHO criteria for a screening test in low-resource settings. The NG LFA in male urine specimens met sensitivity criteria but did not meet the criteria for specificity.